## 2-(3-Phenyl-1-indazolyl)acetic acid methyl ester
This compound, also known as **Indomethacin**, is a non-steroidal anti-inflammatory drug (NSAID). It is **important for research** due to its various pharmacological properties and applications, including:
**1. Analgesic and Anti-inflammatory Effects:**
* Indomethacin is a potent inhibitor of cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2.
* COX enzymes are responsible for the production of prostaglandins, which are involved in inflammation, pain, and fever.
* By inhibiting COX, indomethacin reduces the production of prostaglandins, thus alleviating pain and inflammation.
**2. Antipyretic Properties:**
* Indomethacin can effectively reduce fever by acting on the hypothalamus, the body's temperature control center.
**3. Research Applications:**
* **Understanding inflammation:** Indomethacin has been widely used in research to study the role of prostaglandins in various inflammatory conditions, such as arthritis, gout, and inflammatory bowel disease.
* **Drug development:** It serves as a model compound for the development of new NSAIDs with improved efficacy and safety profiles.
* **Cancer research:** Indomethacin exhibits anti-cancer properties and is being investigated for its potential use in treating certain types of cancer.
* **Neuroprotection:** Some studies suggest that indomethacin may offer neuroprotective effects against stroke and Alzheimer's disease.
**4. Clinical Applications:**
* Indomethacin is prescribed for the treatment of a range of inflammatory conditions, including:
* Rheumatoid arthritis
* Osteoarthritis
* Ankylosing spondylitis
* Gout
* Migraine headaches
* Menstrual cramps
**5. Side Effects:**
* Indomethacin can cause a number of side effects, including gastrointestinal ulcers, bleeding, and kidney problems.
* It is important to use indomethacin under the guidance of a healthcare professional.
**Conclusion:**
2-(3-Phenyl-1-indazolyl)acetic acid methyl ester (Indomethacin) is an important research tool and a clinically significant drug due to its potent analgesic and anti-inflammatory effects. It continues to be valuable in understanding inflammation, drug development, and exploring new therapeutic applications.
| ID Source | ID |
|---|---|
| PubMed CID | 3243873 |
| CHEMBL ID | 1304603 |
| CHEBI ID | 92656 |
| SCHEMBL ID | 15631853 |
| Synonym |
|---|
| MLS000095820 , |
| smr000031368 |
| methyl (3-phenyl-1h-indazol-1-yl)acetate |
| BRD-K37150847-001-05-1 |
| AKOS002137552 |
| 897776-15-7 |
| inz-1 |
| methyl 2-(3-phenylindazol-1-yl)acetate |
| HMS2466J11 |
| BRD-K37150847-001-07-7 |
| CHEMBL1304603 |
| MLS003271343 |
| SCHEMBL15631853 |
| 3-phenyl-1h-indazole-1-acetic acid methyl ester |
| CHEBI:92656 |
| inz-1, >=98% (hplc) |
| 2-(3-phenyl-1-indazolyl)acetic acid methyl ester |
| Q27164366 |
| HY-116686 |
| bdbm192010 |
| mfcd15093813 |
| CS-0066279 |
| inz 1 |
| inz1 |
| Class | Description |
|---|---|
| alpha-amino acid ester | The amino acid ester derivative obtained the formal condensation of an alpha-amino acid with an alcohol. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 28.1838 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 50.1187 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 29.0929 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 35.4813 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 2.8184 | 0.2818 | 9.7212 | 35.4813 | AID2326 |
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 19.9526 | 0.0018 | 15.6638 | 39.8107 | AID894 |
| huntingtin isoform 2 | Homo sapiens (human) | Potency | 35.4813 | 0.0006 | 18.4198 | 1,122.0200 | AID1688 |
| histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 15.8489 | 0.0103 | 23.8567 | 63.0957 | AID2662 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 89.1251 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 12.5893 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 6.3096 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 0.3162 | 0.5623 | 9.3985 | 25.1189 | AID652106 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 2.2387 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 11.2202 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Cytochrome b | Homo sapiens (human) | IC50 (µMol) | 26.7060 | 0.0050 | 2.7548 | 8.0920 | AID1801889 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| heat shock protein 90 | Candida albicans | EC50 (µMol) | 62.0447 | 0.1200 | 6.4855 | 33.8530 | AID2387; AID2400; AID2423 |
| calcineurin A1, putative | Candida dubliniensis CD36 | EC50 (µMol) | 180.0000 | 4.6630 | 6.3810 | 8.0990 | AID2388 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| calcineurin A1, putative | Candida dubliniensis CD36 | AC50 | 1.2640 | 0.6513 | 1.9383 | 3.5430 | AID488836 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1801889 | Cytochrome b Enzyme Assay from Article 10.1016/j.chembiol.2016.06.016: \\A Fungal-Selective Cytochrome bc1 Inhibitor Impairs Virulence and Prevents the Evolution of Drug Resistance.\\ | 2016 | Cell chemical biology, 08-18, Volume: 23, Issue:8 | A Fungal-Selective Cytochrome bc |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.35) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||